Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2017 – Multiple Myeloma
ASCO 2017 – Multiple Myeloma
CALGB/ECOG 100104 (Alliance) Study: Lenalidomide versus Placebo Maintenance After Stem-Cell Transplant for Patients with MM—OS and PFS Adjusted for Treatment Crossover
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
This phase 3 study compared lenalidomide maintenance versus placebo after stem-cell transplant in patients with newly diagnosed multiple myeloma, adjusting overall survival (OS) and progression-free survival (PFS) for treatment crossover.
Read Article
Impact of Post-ASCT Maintenance Therapy on Outcomes in Patients with NDMM Using the Large, Prospective Community-Based Connect MM Registry
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
Insights from the Connect MM Registry show that lenalidomide maintenance therapy after autologous stem-cell transplant (ASCT) significantly improves progression-free survival and overall survival in patients with newly diagnosed multiple myeloma (NDMM).
Read Article
Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM: Efficacy and Safety Update (POLLUX)
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
An update on the POLLUX study has shown that daratumumab, lenalidomide, and dexamethasone improves efficacy outcomes in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Phase 3 ELOQUENT-2 Study: Extended 4-Year Follow-Up of Elotuzumab plus Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
The 4-year follow-up of the ELOQUENT-2 study examining elotuzumab plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) shows sustained safety and efficacy results.
Read Article
Daratumumab, Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in RRMM: Efficacy and Safety Update (CASTOR)
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
Researchers from the CASTOR trial provided an update on the efficacy and safety of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Trends in Survival and Costs Among US Patients with Multiple Myeloma
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
This study examined the trends in survival and healthcare costs of US patients with multiple myeloma from 2006 to 2014.
Read Article
Comparative Efficacy of MM Therapies for Treatment of First Relapse: A Systematic Literature Review and Network Meta-Analysis
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse.
Read Article
Racial Differences in Abnormalities by FISH in Minorities with Multiple Myeloma: A Single-Center Experience
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma.
Read Article
Cost-Effectiveness of Carfilzomib, Ixazomib, Elotuzumab, or Daratumumab with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM).
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma